Focus: Annexon Biosciences is a public-stage biotechnology company focused on neurodegenerative and autoimmune disorders, with a dual-asset pipeline in Phase 3 development targeting high-unmet-need indications. The company operates from Brisbane, California with a lean, focused therapeutic strategy centered on immunology and neurology.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
A high-risk, high-reward clinical-stage biotech suitable for professionals seeking pipeline involvement and equity exposure, but unsuitable if you need revenue-backed stability or rapid career progression through scale.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Annexon Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Annexon Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+1 more
+2 more
Age-related Macular Degeneration Clinical Trial Pipeline: - GlobeNewswire
Age-related Macular Degeneration Clinical Trial Pipeline: GlobeNewswire
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout - Yahoo Finance
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout Yahoo Finance
MindWalk Touts Proven Biology as the Brains Behind Its AI Drug Engine - BriefGlance
MindWalk Touts Proven Biology as the Brains Behind Its AI Drug Engine BriefGlance
Goldman Sachs initiates Annexon Biosciences stock at Neutral on GA trial uncertainty - Investing.com
Goldman Sachs initiates Annexon Biosciences stock at Neutral on GA trial uncertainty Investing.com
Jefferies reiterates Annexon Biosciences stock rating on M&A activity - Investing.com
Jefferies reiterates Annexon Biosciences stock rating on M&A activity Investing.com
8-K Filing: Annexon, Inc. (ANNX) (CIK 0001528115) — EX-99.1
EX-99.1
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
An Open-Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease.
Accelerating medicines to patients: A Bayesian quantitative evidence-based decision-making framework with interim monitoring.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo